AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12585015 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening measures for high-risk indicators
Number of subjects: 0
Study 12585015 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal treatment early in psychosis
Number of subjects: 0
Study 12585015 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health impact of screening
Number of subjects: 0
Study 10467265 — intervention group
Group type: COMPARATOR
Intervention: Approximately 0.34T, 30 stimuli, once a day
Number of subjects: 49
Study 10467265 — intervention group
Group type: EXPERIMENTAL
Intervention: Approximately 0.34T, 30 stimuli, twice a day
Number of subjects: 49
Study 10467265 — intervention group
Group type: EXPERIMENTAL
Intervention: Approximately 0.57T, 30 stimuli, twice a day
Number of subjects: 49
Study 10467265 — intervention group
Group type: EXPERIMENTAL
Intervention: Approximately 0.80T, 30 stimuli, twice a day
Number of subjects: 49
Study 7589044 — intervention group
Group type: EXPERIMENTAL
Intervention: pravastatin 40 mg o.d. for 8 weeks
Number of subjects: 19
Study 7589044 — intervention group
Group type: COMPARATOR
Intervention: placebo for 8 weeks
Number of subjects: 19
Study 1701029 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐64077 (800 mg)
Number of subjects: 8
Study 1701029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6124186 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 38
Study 6124186 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfatesine
Number of subjects: 38
Study 6124186 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane with surgery
Number of subjects: 38
Study 6124186 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfatesine with surgery
Number of subjects: 38
Study 31318128 — intervention group
Group type: EXPERIMENTAL
Intervention: Caplacizumab
Number of subjects: 0
Study 27311618 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intravenous fluid resuscitation (IVFR) with lactated Ringer's solution (initial bolus of 10 mL/kg before the procedure, 3 mL/kg/h during the procedure, for 8 hours after the procedure, and a post‐procedure bolus of 10 mL/kg)
Number of subjects: 510
Study 27311618 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous fluid resuscitation (IVFR) with lactated Ringer's solution at 1.5 mL/kg/h during and for 8 hours after the procedure
Number of subjects: 510
Study 26169566 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive Training (CT)
Number of subjects: 18
Study 26169566 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study 23802031 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in nursing documentation
Number of subjects: 39
Study 23802031 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 39
Study 20094804 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in UI episodes (>=50%)
Number of subjects: 59
Study 20094804 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in I-QOL scores (>=10 points)
Number of subjects: 59
Study 20094804 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall change in daily UI episodes
Number of subjects: 59
Study 20094804 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall change in I-QOL scores
Number of subjects: 59
Study 20094804 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall change in SF-6D scores
Number of subjects: 59
Study 18984908 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational quality improvement intervention
Number of subjects: 64
Study 17007699 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving treatment for primary care (PST-PC) combined with elements from motivational interviewing
Number of subjects: 0
Study 17007699 — intervention group
Group type: EXPERIMENTAL
Intervention: DCS nurses' interventions
Number of subjects: 0
Study 12729121 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate physiotherapy within one week (group A)
Number of subjects: 86
Study 12729121 — intervention group
Group type: COMPARATOR
Intervention: Delayed physiotherapy after three weeks of immobilisation (group B)
Number of subjects: 86
Study 11051189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine (100 mg in 50 cc of saline)
Number of subjects: 60
Study 11051189 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 60
Study 8816215 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 40
Study 8816215 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 40
Study 8816215 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 40
Study 1487226 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (G)
Number of subjects: 178
Study 1487226 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (B)
Number of subjects: 178
Study 2866672 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation (TNS)
Number of subjects: 72
Study 2866672 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 72
Study 2866672 — intervention group
Group type: COMPARATOR
Intervention: Intravenous meperidine
Number of subjects: 72
Study 31061021 — intervention group
Group type: EXPERIMENTAL
Intervention: Current clinical practice (300 U/mL)
Number of subjects: 88
Study 31061021 — intervention group
Group type: COMPARATOR
Intervention: NMJ-targeted injection (100 U/mL)
Number of subjects: 88
Study 30594222 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 162 mg administered subcutaneously once weekly for 24 weeks
Number of subjects: 24
Study 30594222 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered subcutaneously once weekly for 24 weeks
Number of subjects: 24
Study 30594222 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 24
Study 27391223 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine, Chlorthalidone, or Lisinopril (antihypertensive treatment)
Number of subjects: 31250
Study 24840230 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of physical activity before diagnosis
Number of subjects: 521
Study 24840230 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of physical activity after diagnosis
Number of subjects: 521
Study 24840230 — intervention group
Group type: COMPARATOR
Intervention: Physical activity
Number of subjects: 521
Study 22471345 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 1.5-3 ng/ml
Number of subjects: 224
Study 22471345 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus 4-7 ng/ml
Number of subjects: 224
Study 22471345 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus tacrolimus minimization
Number of subjects: 224
Study 20438585 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Mathieu and Snodgrass urethroplasty
Number of subjects: 101
Study 20438585 — intervention group
Group type: COMPARATOR
Intervention: Mathieu urethroplasty
Number of subjects: 101
Study 20438585 — intervention group
Group type: COMPARATOR
Intervention: Snodgrass urethroplasty
Number of subjects: 101
Study 18041050 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes mellitus (T1DM) subjects during isometric exercise
Number of subjects: 0
Study 18041050 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes mellitus (T1DM) subjects
Number of subjects: 0
Study 18041050 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 17425231 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (53 hours)
Number of subjects: 26
Study 15573919 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg)
Number of subjects: 50
Study 15573919 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 ml saline)
Number of subjects: 50
Study 10886047 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent ranitidine 150 mg b.d.
Number of subjects: 155
Study 10886047 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate antacids
Number of subjects: 155
Study 9376042 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1 mg/kg/h after a priming dose of 1 mg/kg)
Number of subjects: 45
Study 9376042 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-hydroxybutyrate (25 mg/kg/h after a priming dose of 25 mg/kg)
Number of subjects: 45
Study 9376042 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 45
Study 8322373 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue‐type plasminogen activator (0.85 mg/kg) within 90 minutes
Number of subjects: 27
Study 8322373 — intervention group
Group type: COMPARATOR
Intervention: Placebo within 90 minutes
Number of subjects: 27
Study 8322373 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue‐type plasminogen activator (0.85 mg/kg) from 91 to 180 minutes
Number of subjects: 27
Study 8322373 — intervention group
Group type: COMPARATOR
Intervention: Placebo from 91 to 180 minutes
Number of subjects: 27
Study 8322373 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 27
Study 3539623 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil 200 mg once daily
Number of subjects: 27
Study 3539623 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil 200 mg twice daily
Number of subjects: 27
Study 3539623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 31990061 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31061057 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral training (personalised pelvic floor muscle training programme)
Number of subjects: 363
Study 31061057 — intervention group
Group type: COMPARATOR
Intervention: Conventional training (maximal pelvic floor muscle contraction assessed by digital rectal examination)
Number of subjects: 363
Study 31061057 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 363
Study 30086538 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy (60 min sessions for 8 weeks)
Number of subjects: 70
Study 30086538 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 70
Study 26863442 — intervention group
Group type: EXPERIMENTAL
Intervention: SHAM (0.1 g·kg(‐1) NaCl, 4 mL·kg(‐1) carbonated water, and 1 mL·kg(‐1) squash)
Number of subjects: 8
Study 26863442 — intervention group
Group type: COMPARATOR
Intervention: PLA (0.1 g·kg(‐1) sodium chloride (NaCl), 4 mL·kg(‐1) tap water, and 1 mL·kg(‐1) squash)
Number of subjects: 8
Study 26863442 — intervention group
Group type: EXPERIMENTAL
Intervention: SHAM
Number of subjects: 8
Study 26863442 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 8
Study 24736440 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine dosed according to World Health Organization weight bands
Number of subjects: 45
Study 24736440 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of zidovudine
Number of subjects: 45
Study 24736440 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger and underweight children
Number of subjects: 45
Study 24736440 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine exposure
Number of subjects: 45
Study 22648714 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone intake of ≥10 mg/d
Number of subjects: 9514
Study 19333002 — intervention group
Group type: EXPERIMENTAL
Intervention: Shan 5
Number of subjects: 400
Study 19333002 — intervention group
Group type: COMPARATOR
Intervention: Easyfive
Number of subjects: 400
Study 19333002 — intervention group
Group type: COMPARATOR
Intervention: TritanrixHB + Hiberix
Number of subjects: 400
Study 17891596 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone (10 mg/day on days 1-14)
Number of subjects: 104
Study 17891596 — intervention group
Group type: COMPARATOR
Intervention: Placebo (days 15-28 of each cycle)
Number of subjects: 104
Study 17891596 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Number of subjects: 104
Study 17891596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 17891596 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone and Placebo
Number of subjects: 104
Study 14693594 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine with 10% dextrose
Number of subjects: 8
Study 14693594 — intervention group
Group type: COMPARATOR
Intervention: 2-chloroprocaine with saline
Number of subjects: 8
Study 12411035 — intervention group
Group type: EXPERIMENTAL
Intervention: CSEA group
Number of subjects: 300
Study 12411035 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide group
Number of subjects: 300
Study 12411035 — intervention group
Group type: COMPARATOR
Intervention: CSEA group, Nitrous oxide group, Control group
Number of subjects: 300
Study 9526519 — intervention group
Group type: EXPERIMENTAL
Intervention: Supranormal oxygen delivery and consumption therapy (volume expansion and dobutamine 3 to 15 micrograms/kg/min for 12 hours)
Number of subjects: 34
Study 9526519 — intervention group
Group type: COMPARATOR
Intervention: Normal hemodynamic values therapy (control group)
Number of subjects: 34
Study 7976820 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 7
Study 7976820 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution
Number of subjects: 7
Study 2498513 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold sodium thiomalate (GSTM) 50 mg IM weekly + placebo
Number of subjects: 35
Study 2498513 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 12.5 mg weekly (oral and noncycled) + placebo
Number of subjects: 35
Study 2498513 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 35
Study 2498513 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (GSTM and MTX)
Number of subjects: 35
Study 31168085 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (specific dosage and duration not mentioned)
Number of subjects: 1015
Study 28608447 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study 26138912 — intervention group
Group type: EXPERIMENTAL
Intervention: Recursive partitioning analysis (RPA)
Number of subjects: 703
Study 26138912 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for overall survival (OS)
Number of subjects: 703
Study 23962828 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive Individualized Training (NIT)
Number of subjects: 72
Study 23962828 — intervention group
Group type: COMPARATOR
Intervention: Social Skills Individualized Training (SSIT)
Number of subjects: 72
Study 20959555 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg)
Number of subjects: 150
Study 20959555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 19472437 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination containing acetylsalicylic acid, paracetamol, and caffeine (randomized phase)
Number of subjects: 1734
Study 19472437 — intervention group
Group type: EXPERIMENTAL
Intervention: Single agents acetylsalicylic acid and paracetamol (randomized phase)
Number of subjects: 1734
Study 19472437 — intervention group
Group type: COMPARATOR
Intervention: Triple combination containing acetylsalicylic acid, paracetamol, and caffeine (open-label phase)
Number of subjects: 1734
Study 19472437 — intervention group
Group type: COMPARATOR
Intervention: Single agents acetylsalicylic acid, paracetamol, and ibuprofen (open-label phase)
Number of subjects: 1734
Study 19472437 — intervention group
Group type: COMPARATOR
Intervention: Single agents acetylsalicylic acid and paracetamol (open-label phase)
Number of subjects: 1734
Study 17301210 — intervention group
Group type: EXPERIMENTAL
Intervention: Durable Display at Discharge (3D)
Number of subjects: 138
Study 17301210 — intervention group
Group type: COMPARATOR
Intervention: Medication Discharge Worksheet (MDW)
Number of subjects: 138
Study 15482446 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional statements
Number of subjects: 0
Study 15482446 — intervention group
Group type: COMPARATOR
Intervention: Neutral statements
Number of subjects: 0
Study 15281970 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% (single drop)
Number of subjects: 23
Study 15281970 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single drop)
Number of subjects: 23
Study 11059636 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil, 8 or 16 mg once daily
Number of subjects: 5000
Study 11059636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5000
Study 9216967 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebreathing expired air, face covered by bedding material
Number of subjects: 41
Study 9216967 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to hypercarbia, face uncovered
Number of subjects: 41
Study 8444272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (750 mg daily for 2-3 weeks)
Number of subjects: 7
Study 3523551 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-neon (He-Ne) laser treatment
Number of subjects: 30
Study 3523551 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 30
Study 30286507 — intervention group
Group type: EXPERIMENTAL
Intervention: Short term cognitive psychotherapy
Number of subjects: 88
Study 30286507 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic psychotherapy
Number of subjects: 88
Study 30286507 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial attachment characteristics
Number of subjects: 88
Study 27015689 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor and cognitive rehabilitation (20-week programme consisting of active self-correction, task-oriented exercises, and cognitive-behavioural therapy)
Number of subjects: 130
Study 27015689 — intervention group
Group type: COMPARATOR
Intervention: General physiotherapy (active and passive mobilizations, stretching, and strengthening exercises of the spinal muscles)
Number of subjects: 130
Study 27015689 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor and cognitive rehabilitation
Number of subjects: 130
Study 24336884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate
Number of subjects: 20
Study 24336884 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (AZ)
Number of subjects: 20
Study 22419263 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TA) group (n = 25, 500 mg/5 ml tranexamic acid)
Number of subjects: 50
Study 22419263 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25, 5 ml 0.9% saline)
Number of subjects: 50
Study 20013115 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg regular release (RR)
Number of subjects: 0
Study 20013115 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg sustained release (SR)
Number of subjects: 0
Study 20013115 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg surge-sustained release (SSR)
Number of subjects: 0
Study 20013115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18684855 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg twice a day for 12 weeks
Number of subjects: 214
Study 18684855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 17117564 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for 3-4 weeks, 5 times each week, plus routine therapy
Number of subjects: 40
Study 17117564 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy alone
Number of subjects: 40
Study 14685287 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus group (10 units of oxytocin administered over 30 seconds)
Number of subjects: 90
Study 14685287 — intervention group
Group type: EXPERIMENTAL
Intervention: Drip group (10 units of oxytocin administered over 5 minutes)
Number of subjects: 90
Study 14685287 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oxytocin administration)
Number of subjects: 90
Study 10588557 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine alone (group I)
Number of subjects: 20
Study 10588557 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine + epinephrine (group II)
Number of subjects: 20
Study 8916620 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized estimating equations (GEE) method for controlling within-cluster correlation in regression models.
Number of subjects: 0
Study 8916620 — intervention group
Group type: EXPERIMENTAL
Intervention: GEE-independent method
Number of subjects: 0
Study 1676715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1676715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 25
Study 1676715 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 25
Study 6408300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 60
Study 6408300 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitroglycerin)
Number of subjects: 60
Study 31194704 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial Incentives (FI)
Number of subjects: 76
Study 31194704 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 76
Study 28284785 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab
Number of subjects: 468
Study 25552412 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 10 mL 10% calcium gluconate in 100 mL 0.9% saline solution
Number of subjects: 200
Study 25552412 — intervention group
Group type: COMPARATOR
Intervention: Placebo group received 100 mL 0.9% saline solution
Number of subjects: 200
Study 23330988 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-supported fixed prostheses (Group A)
Number of subjects: 40
Study 23330988 — intervention group
Group type: COMPARATOR
Intervention: Overdentures (Group B)
Number of subjects: 40
Study 20869050 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 631
Study 20869050 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 631
Study 19103360 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet B (NB UVB)
Number of subjects: 13
Study 19103360 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose ultraviolet A1 (MD UVA1)
Number of subjects: 13